Literature DB >> 22261253

ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF.

Laëtitia Andrique1, Dominique Fauvin, Mahmoud El Maassarani, Hélène Colasson, Brigitte Vannier, Paule Séité.   

Abstract

EGFR family members are tyrosine kinase transmembrane receptors that, in response to specific extracellular ligands, activate cytoplasmic pathways involved in cell proliferation, migration and differentiation. More recently, a pivotal role for EGF receptors has emerged, through the description of their nuclear localization.We report here the characterization of a nuclear variant of the kinase-defective ErbB3 receptor, ErbB3(80 kDa), spanning the intracytoplasmic domain of the receptor. We assessed the putative transcriptional functions of ErbB3(80 KDa) in cancer cells, through the regulation of the proliferative Cyclin D1 gene, an already known target of the ErbB3 cytoplasmic signaling. We demonstrate here that the binding of ErbB3(80 KDa) on the promoter activates Cyclin D1 transcription and subsequent protein expression, leading to an increased cell proliferation. This mechanism can be balanced in response to the ectopic expression of the tumor suppressor p14ARF that physically interacts with ErbB3(100 kDa) and sequesters it into nucleoli. Our data also show that ErbB3(80 kDa) increases the transcription of proliferative genes even though the cytoplasmic pathways are not activated. This nuclear ErbB3 pathway and the target genes concerned need to be further studied. Indeed, such mechanism could explain the tumor relapse observed in response to treatments aimed at blocking the receptor activation in response to ligand binding. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261253     DOI: 10.1016/j.cellsig.2012.01.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

1.  Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells.

Authors:  Raymond Reif; Alshaimaa Adawy; Nachiket Vartak; Jutta Schröder; Georgia Günther; Ahmed Ghallab; Marcus Schmidt; Wiebke Schormann; Jan G Hengstler
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

Review 2.  Receptor tyrosine kinases in the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

Review 3.  Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  FEBS J       Date:  2015-07-04       Impact factor: 5.542

Review 4.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors:  Jennifer L Hsu; Mien-Chie Hung
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

5.  Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.

Authors:  R I Cordo Russo; W Béguelin; M C Díaz Flaqué; C J Proietti; L Venturutti; N Galigniana; M Tkach; P Guzmán; J C Roa; N A O'Brien; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

6.  ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Authors:  S E Busch; R D Moser; K E Gurley; K S Kelly-Spratt; H D Liggitt; C J Kemp
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

Review 7.  Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.

Authors:  Laurel E Black; Jody F Longo; Steven L Carroll
Journal:  Am J Pathol       Date:  2019-07-25       Impact factor: 5.770

8.  Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.

Authors:  Toni M Brand; Mari Iida; Neha Luthar; Matthew J Wleklinski; Megan M Starr; Deric L Wheeler
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

9.  Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Authors:  Stephen Hiscox; Bedanta Baruha; Chris Smith; Rebecca Bellerby; Lindy Goddard; Nicola Jordan; Zaruhi Poghosyan; Robert I Nicholson; Peter Barrett-Lee; Julia Gee
Journal:  BMC Cancer       Date:  2012-10-06       Impact factor: 4.430

10.  HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Authors:  Setareh Safavi; Sofia Järnum; Christoffer Vannas; Sameer Udhane; Emma Jonasson; Tajana Tesan Tomic; Pernilla Grundevik; Henrik Fagman; Magnus Hansson; Zeynep Kalender; Alexandra Jauhiainen; Soheila Dolatabadi; Eva Wessel Stratford; Ola Myklebost; Mikael Eriksson; Göran Stenman; Regine Schneider-Stock; Anders Ståhlberg; Pierre Åman
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.